An Oncology News-fest, during ASCO week:
Genentech’s Avastin shown to be helpful for kidney cancer.
Bayer/Onyx’s Nexavar shows hopeful activity for liver cancer.
Pfizer’s still-experimental axitinib shows hopeful results with advanced thyroid cancer.
Sprycel creeping up on Gleevec as a potential first line treatment for leukemia.
Bristol’s experimental drug derived from African soil may delay progression of advanced breast cancer.
A hopeful early result for an experimental Pfizer drug for melanoma.
Celgene study of Revlimid in myeloma shows that lower steroid dose leads to better results.
Arsenic – another poison that’s good for you (in small doses!): Cephalon’s Trisenox with an impressive result for leukemia.
In the “let’s try to get some sanity to counter-balance screaming headlines” department, some take-a-chill-pill perspectives on the Avandia debate, and the Epo safety discussion. It is pretty interesting what a little attention to on-label usage might do…
J&J – possibly an important new advance against drug-resistant TB!
Finally, on the lighter side, a new wonder drug that just may end all the Big Pharma bashing!